Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
J Intern Med. 2014 Apr;275(4):364-81. doi: 10.1111/joim.12204. Epub 2014 Mar 17.
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.
多发性硬化症（MS）主要是中枢神经系统的自身免疫性疾病，但也包含明显的神经退行性方面。随着时间的推移，很大一部分 MS 患者会出现神经功能障碍，直到最近，治疗选择一直受到限制。然而，MS 的治疗现在正处于快速发展阶段，有几种新药已经上市或即将在不久的将来推出。这为个性化治疗提供了新的机会，但也带来了新的挑战，包括疾病活动的监测、长期安全性问题和疗效，尤其是在进展性疾病患者中。
